This company has shut down. Kalaris Therapeutics (formerly AlloVir) is no longer operating — its last tracked round was a Post-IPO Equity in 2025.
Explore the Startup GraveyardAlloVir focuses on the development of cell therapies and focuses on restoring natural immunity against the virus-associated diseases.
Kalaris Therapeutics (formerly AlloVir) has raised $50.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in December 2025.
Kalaris Therapeutics (formerly AlloVir)'s investors include Gilead Sciences, Redmile Group, Fidelity, Samsara BioCapital, RTW Investments.
Kalaris Therapeutics (formerly AlloVir) is headquartered in Houston, United States.
AlloVir focuses on the development of cell therapies and focuses on restoring natural immunity against the virus-associated diseases.
Kalaris Therapeutics (formerly AlloVir) is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Kalaris Therapeutics (formerly AlloVir) — Funding & Investors." VCBacked, December 17, 2025, https://www.vcbacked.co/company/kalaris-therapeutics-formerly-allovir. Accessed August 14, 2026.
VCBacked. (2025). Kalaris Therapeutics (formerly AlloVir) — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/kalaris-therapeutics-formerly-allovir
{{cite web |title=Kalaris Therapeutics (formerly AlloVir) — Funding & Investors |url=https://www.vcbacked.co/company/kalaris-therapeutics-formerly-allovir |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated